Curis Lifesciences Ltd.

13th August, 2026

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5" Floor, Plot No. C/1
G Block, Bandra-Kurla Complex, Bandra (E)
Mumbai — 400051
Scrip Symbol: CURIS

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 (“LODR Regulations”)

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that, Curis Lifesciences Limited (the Company) has agreed to make a strategic investment in CUROSUN PHARMACEUTICAL NIG LTD (the Investee Company), a company incorporated in Nigeria, by acquiring Ordinary shares equivalent to 49.95% of the Investee Company. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR Regulations") is enclosed as Annexure I.

Thanking you,
Yours Faithfully

FOR CURIS LIFESCIENCES LIMITED

PATEL JAIMIK MANSUKHLAL
Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.08.13 18:57:32 +05'30'

JAIMIK MANSUKHLAL PATEL
WHOLE-TIME DIRECTOR
DIN: 07371003

Annexure I

Information as required under Regulation 30 - Part A of Para A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	
1.	Name of the target entity, details in brief such as size and turnover.	Name: CUROSUN PHARMACEUTICAL NIG LTD (Nigerian Company) Registration Number: 9471048 Date of Registration: April 7, 2026 Company Type: Private Company Limited by Shares Company Address: 20, OGUNAIKE STREET, PALMGROVE, SHOMOLU, LAGOS STATE Business Activity: Importation and Sales of Drugs, Medicines, Distribution and Wholesale Business of Drugs and Medicine in all its ramifications. Total Ordinary Shares: 100,000,000 (ONE HUNDRED MILLION) Total Share Capital: 100,000,000 NAIRA (ONE HUNDRED MILLION NAIRA) Nominal value of each share issued: 1 Turnover: 0
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	The acquisition doesn't fall within the purview of related party transactions. None of the promoter/ promoter group/ group companies of listed entity have any interest in the entity being acquired. *Additional Disclosure:* The shares of the Investee Company were initially subscribed **MR. JAIMIK MANSUKHLAL PATEL, Whole-time Director (WTD)** of the Company, for administrative convenience. The said shares have now been transferred to **Curis Lifesciences Limited** at cost (at par), without any profit or financial benefit accruing to the Director. The

		acquisition/transfer has been executed on an **arm's length basis**.
3.	Industry to which the entity being acquired belongs	The target company is engaged into the business of importation, distribution and wholesale Drugs and Medications.
4.	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity).	This acquisition aligns with the Company's strategic growth initiatives aimed at business expansion, diversification and strengthening of its market presence in the pharmaceutical industry. Curis Lifesciences Limited ("Curis") has entered into a Joint Venture Agreement ("JV Agreement") by acquiring 49.95% of shares in CUROSUN PHARMACEUTICAL NIG LTD
5.	Brief details of any governmental or regulatory approvals required for the acquisition	For Automatic Route, no prior approval of RBI is required.
6.	Indicative time period for completion of the acquisition	The acquisition is made on 12th August 2026.
7.	Nature of consideration – whether cash consideration or share swap and details of the same.	Cash Consideration of Rs. 5,00,000 (Rs. Five Lakhs only)
8.	Cost of acquisition or the price at which the shares are acquired.	The acquisition is being undertaken for a total Purchase consideration of Rs. 5,00,000 (Rs. Five Lakhs only)
9.	Percentage of shareholding /Control acquired and / or number of shares acquired.	Acquisition of 49.95% of Share capital in the Investee Company.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, and history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief).	CUROSUN PHARMACEUTICAL NIG LTD is a company incorporated in Nigeria, having registration number 9471048, involved in Importation and Sales of Drugs, Medicines, Distribution and Wholesale Business of Drugs and Medicine in all its ramifications. Total Ordinary Shares: 100,000,000 (ONE HUNDRED MILLION) Total Share Capital: 100,000,000 (ONE HUNDRED MILLION) Nominal value of each share issued: 1 Turnover: 0